首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1410110

即時 (POC) 基因檢測市場：2023 年至 2028 年預測

Point-of-Care Genetic Testing Market - Forecasts from 2023 to 2028

出版日期: 2023年12月18日 | 出版商:

Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計在預測期內，即時護理 (POC) 基因檢測市場將以 12.08% 的複合年成長率成長。

隨著技術進步使基因檢測能力更接近患者的照護端，照護端 (POC) 基因檢測市場正在迅速擴大。即時檢測 (POC) 基因檢測是在標準實驗室之外進行的基因檢測，可實現即時觀察和決策。這個市場類別包括各種測試設備和套件，使醫療保健專業人員能夠快速分析遺傳資料並做出明智的治療決策。對個體化治療、早期疾病診斷和輕鬆獲得基因檢測的需求不斷成長，正在推動即時 (POC) 基因檢測市場的發展。此外，攜帶式和手持式檢測技術的市場開拓以及基因檢測價格的下降正在推動市場擴張。即時護理 (POC) 基因檢測市場的成長為醫療保健服務的徹底變革提供了廣闊的前景，因為它能夠改善患者的治療結果並實現個體化治療方法。

即時（POC）基因檢測市場對個人化醫療和精準醫療的需求不斷成長

對個體化和精準治療日益成長的需求正在推動即時護理 (POC) 基因檢測市場的發展。個人化醫療和精準醫療涉及根據遺傳、生活方式和環境因素對每位患者進行個體化醫療。這種方法可以實現更準確的診斷、量身定做的治療和更好的治療結果。隨著患者和醫療保健提供者認知到個人化醫療提供更有效和個體化治療的承諾，對能夠在治療時提供快速、準確的遺傳資訊的基因檢測技術的需求正在增加。收集準確的基因資料的能力使醫療保健提供者能夠就治療策略、藥物選擇和預防措施做出明智的決策，從而推動對即時 (POC) 基因檢測解決方案的需求。

對遺傳疾病的認知和理解不斷提高，加強了即時 (POC) 基因檢測市場

對遺傳疾病的認知和了解不斷增加是推動即時（POC）基因檢測產業成長的主要因素。隨著大眾對基因突變對健康影響的了解不斷擴大，個人和醫療保健專業人員在檢測和管理遺傳疾病方面變得更加積極主動。教育工具、公眾意識宣傳活動和遺傳諮詢服務都有助於更好地了解遺傳疾病。這種知識的增加促進了資訊資訊診斷、個性化治療方法和明智的決策。這一需求正在不斷成長。醫療保健領域對遺傳疾病的日益關注導致基因檢測的使用範圍擴大，推動了即時 (POC) 基因檢測市場的成長。

即時檢測能力的擴展將推動即時（POC）基因檢測市場的發展

床邊檢測能力的擴展是床邊檢測（POC）基因檢測市場成長的關鍵驅動力。即時護理測試是指在患者附近進行診斷測試並提供即時資料以幫助緊急決策。隨著技術的進步，POC 檢測設備的性能得到提高，使得在照護端進行更複雜的基因檢測成為可能。這項進步使醫護人員能夠接收即時遺傳資訊，而無需將樣本提交給中央檢測機構。能夠進行先進基因分析的攜帶式和手持式診斷設備的出現增加了便利性，減少了周轉時間，並改善了患者的治療結果。床邊檢測能力的增強使醫護人員能夠做出更快、更資訊的決策，從而推動了對床邊 (POC) 基因檢測解決方案的需求。

北美是即時護理（POC）基因檢測市場的領導者

北美已成為即時檢測 (POC) 基因檢測市場的領導者。有幾個因素促成了該地區的主導地位。北美醫療體系技術先進，遺傳性疾病發生率高，強調個體化治療。此外，該地區還受益於研發方面的高額支出、醫療機構和技術公司之間的合作以及鼓勵使用即時護理 (POC) 基因檢測的有利法律規章。主要市場參與者的存在以及現代測試設備和套件的可用性有助於北美的優勢。但值得注意的是，全球即時檢測（POC）基因檢測的市場規模正在擴大，歐洲和亞太等其他地區也看到了該產業的重大突破。

即時檢測 (POC) 基因檢測市場的快速結果和及時決策

在即時檢測 (POC) 基因檢測業務中，快速發現和快速決策是關鍵。傳統的基因檢測需要將樣本運送到中央設施，這可能會延遲獲得觀察。另一方面，即時護理 (POC) 基因檢測的優點是可以在患者所在地快速提供觀察，使醫療保健專業人員能夠快速做出選擇。如此快速的反應可以實現快速介入、個體化治療策略和更好的患者治療效果。及時獲取遺傳資訊的能力可以提高醫療服務的效率，減少患者等待觀察的時間，並能夠快速做出有關治療方案、預防措施和諮詢的決策。快速觀察和快速決策是在各種醫療保健環境中使用即時護理 (POC) 基因檢測技術的重要動機。

主要進展

2022 年 8 月，生命科學研究和臨床診斷產品領域的全球領導者 Bio-Rad Laboratories 宣布達成協議，收購 Curiosity Diagnostics 的所有已發行股。 Zoo 的所有已發行，Scope Fluidics, SA 是一家總部位於波蘭華沙的醫療診斷和醫療保健市場創新技術解決方案開發商，總代價為1.7 億美元，其中包括約1 億美元現金。他們宣布已同意收購最大金額。

公司產品

ID NOW(TM) 分子平台： ID NOW 平台提供即時分子偵測。雅培實驗室提供各種感染疾病感染疾病，包括呼吸道和胃腸道感染疾病。這種攜帶式診斷小工具可在幾分鐘內產生觀察，從而可以快速診斷和選擇治療方法方法。
Cobas(R) Riat(R) 系統： Cobas(R) Riat(R) 系統是一個小型攜帶式平台，能夠進行即時分子診斷。我們可以傳染病檢查，包括流感、呼吸道融合細胞病毒(RSV) 和 A 型溶血性鏈球菌。該技術可在 20 分鐘內產生可靠的資料，從而實現快速診斷和治療選擇。
QIAstat-Dx： QIAstat-Dx 系統是一個完全整合的分子診斷平台，專為快速、準確的即時偵測而設計。我們提供針對呼吸道疾病、胃腸道疾病和其他感染疾病的多種測試。該設備將樣品製備、擴增和檢測整合在試劑盒中，並在一小時內提供結果。
Cepheid GeneXpert 系統： GeneXpert 系統是一個完全整合的分子診斷平台，可在照護端進行快速、準確的測試。我們提供廣泛的傳染病檢查，包括呼吸道疾病、性行為感染和醫療保健相關感染疾病。此技術可自動進行樣品製備、擴增和檢測，並可在數小時內提供觀察。

The point-of-care genetic testing market is rapidly expanding as technological advances bring genetic testing capabilities closer to the patient's point of care. Point-of-care genetic testing is genetic testing that is performed outside of standard laboratory settings, allowing for real-time findings and decision-making. This market category comprises a wide range of testing instruments and kits that allow healthcare practitioners to swiftly analyse genetic data and make educated treatment decisions. The rising desire for personalised treatment, early illness diagnosis, and easier access to genetic testing are propelling the point-of-care genetic testing market forward. Furthermore, developments in portable and handheld testing technologies, as well as lower genetic testing prices, are fuelling market expansion. The point-of-care genetic testing market growth presents significant prospects for revolutionising healthcare delivery, with the ability to enhance patient outcomes and allow personalised treatment methods.

Increasing Demand for Personalized and Precision Medicine in the Point-of-Care Genetic Testing Market.

The rising need for personalised and precise treatment is driving the Point-of-Care Genetic Testing market. Personalised and precision medicine is concerned with personalising medical treatments to individual patients based on genetics, lifestyle, and environmental factors. This method enables more accurate diagnosis, tailored therapy, and better treatment results. As patients and healthcare providers recognise the promise of personalised medicine to deliver more effective and personalised treatment, there is an increasing need for genetic testing technologies that can give rapid and accurate genetic information at the point of care. The ability to collect exact genetic data allows healthcare providers to make educated decisions about treatment strategies, drug selection, and preventative measures, fuelling demand for Point-of-Care Genetic Testing solutions.

Growing Awareness and Understanding of Genetic Diseases Enhances the Point-of-Care Genetic Testing Market.

Growing knowledge and understanding of genetic illnesses is a major driver of growth in the Point-of-Care Genetic Testing industry. Individuals and healthcare professionals are becoming more proactive in discovering and managing genetic diseases as public knowledge of the influence of genetic variants on health grows. Educational tools, public awareness campaigns, and genetic counselling services have all led to a better understanding of hereditary illnesses. Because of this increased knowledge, there is a greater need for Point-of-Care Genetic Testing solutions that can give rapid and accessible genetic information, supporting early diagnosis, personalised treatment regimens, and informed decision-making. The rising emphasis in healthcare on genetic illnesses has resulted in greater use of genetic testing, fuelling the growth of the Point-of-Care Genetic Testing market.

Expansion of Point-of-Care Testing Capabilities Boosts the Point-of-Care Genetic Testing Market.

The expansion of point-of-care testing capabilities is a critical driver of growth in the Point-of-Care Genetic Testing market. Point-of-care testing is the practice of running diagnostic tests close to the patient and delivering instant data that can assist urgent decision-making. The capabilities of point-of-care testing devices have grown as technology has advanced, enabling for more complex genetic testing to be performed at the point of care. This advancement allows healthcare workers to receive real-time genetic information without having to submit samples to centralized laboratories. The availability of portable and handheld diagnostic instruments capable of sophisticated genetic analysis improves convenience, decreases turnaround time, and improves patient results. The increase in point-of-care testing capabilities enables healthcare practitioners to make more prompt and informed decisions, fuelling demand for Point-of-Care Genetic Testing solutions.

North America is the Market Leader in the Point-of-Care Genetic Testing Market.

North America has emerged as the leader in the point-of-care genetic testing market. Several factors contribute to the region's dominant status. North America's healthcare system is technologically sophisticated, there is a high frequency of genetic illnesses, and there is a significant emphasis on personalised therapy. Furthermore, the area benefits from considerable expenditures in R&D, cooperation between healthcare institutions and technology firms, and favourable legislative rules that encourage the use of point-of-care genetic testing. The presence of important market companies, as well as the availability of modern testing machines and kits, contributes to North America's dominance. However, it is vital to note that the point-of-care genetic testing market size is expanding globally, and other areas such as Europe and Asia-Pacific are also seeing substantial breakthroughs in this industry.

Rapid Results and Timely Decision-Making in Point-of-Care Genetic Testing Market.

In the Point-of-Care Genetic Testing business, quick findings and rapid decision-making are critical. Traditional genetic testing sometimes necessitates transferring samples to centralised facilities, which causes delays in getting findings. Point-of-Care Genetic Testing, on the other hand, has the benefit of presenting findings quickly at the patient's location, allowing healthcare practitioners to make prompt choices. This rapid turnaround time enables quicker intervention, personalised treatment strategies, and better patient results. The capacity to acquire genetic information in a timely way improves healthcare delivery efficiency, lowers the time patients spend waiting for findings and allows for fast decision-making on treatment options, preventative measures, and counselling. Rapid findings and rapid decision-making are important motivators for the use of Point-of-Care Genetic Testing technologies in a variety of healthcare settings.n

Key Developments:

In August 2022, Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, announced that it has agreed to acquire all of the outstanding shares of Curiosity Diagnostics, Sp. Z. o. o. from Scope Fluidics, S.A., a Warsaw, Poland-based developer of innovative technology solutions for the medical diagnostic and healthcare markets, for a total consideration of up to $170 million, including approximately $100 million in cash.

Company Products:

ID NOW™ Molecular Platform: The ID NOW platform offers point-of-care molecular testing. Abbott Laboratories provides a variety of infectious disease diagnostics, including respiratory and gastrointestinal infections. This portable diagnostic gadget generates findings in minutes, allowing for rapid diagnosis and treatment options.
Cobas® Liat® System: The Cobas Liat System is a small and portable platform that offers point-of-care molecular diagnostics. It provides a wide range of infectious illness tests, including influenza, respiratory syncytial virus (RSV), and Group A Streptococcus. Within 20 minutes, the technology produces trustworthy data, allowing for fast diagnosis and treatment options.
QIAstat-Dx: The QIAstat-Dx system is a fully integrated molecular diagnostics platform designed for point-of-care testing that is both quick and accurate. It offers several tests for respiratory, gastrointestinal, and other infectious illnesses. The device integrates sample preparation, amplification, and detection in a single cartridge and produces results in less than an hour.
Cepheid GeneXpert System: The GeneXpert System is a fully integrated molecular diagnostics platform that allows for speedy and precise testing at the point of care. It provides a wide range of infectious disease tests, including respiratory illnesses, sexually transmitted infections, and infections connected with healthcare. The technology automates sample preparation, amplification, and detection and produces findings in hours.

Segmentation:

By Technology

PCR (Polymerase Chain Reaction)
Microarray
Isothermal Amplification
Next-Generation Sequencing (Ngs)
Others

By Test Type

Carrier Testing
Diagnostic Testing
Predictive And Presymptomatic Testing
Prenatal Testing
Newborn Screening
Others

By Application

Cancer Screening
Genetic Diseases
Pharmacogenetics
Personalized Medicine
Others

By End-User

Hospitals And Clinics
Home Care Settings
Research Institutes
Others

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Italy
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Taiwan
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Sources
2.3. Research Design

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. POINT-OF-CARE GENETIC TESTING MARKET, BY TECHNOLOGY

5.1. Introduction
5.2. PCR (POLYMERASE CHAIN REACTION)
5.3. MICROARRAY
5.4. ISOTHERMAL AMPLIFICATION
5.5. NEXT-GENERATION SEQUENCING (NGS)
5.6. OTHERS

6. POINT-OF-CARE GENETIC TESTING MARKET, TEST TYPE

6.1. Introduction
6.2. CARRIER TESTING
6.3. DIAGNOSTIC TESTING
6.4. PREDICTIVE AND PRESYMPTOMATIC TESTING
6.5. PRENATAL TESTING
6.6. NEWBORN SCREENING
6.7. OTHERS

7. POINT-OF-CARE GENETIC TESTING MARKET, APPLICATION

7.1. Introduction
7.2. CANCER SCREENING
7.3. GENETIC DISEASES
7.4. PHARMACOGENETICS
7.5. PERSONALIZED MEDICINE
7.6. OTHER

8. POINT-OF-CARE GENETIC TESTING MARKET, BY END-USER

8.1. Introduction
8.2. HOSPITALS AND CLINICS
8.3. HOME CARE SETTINGS
8.4. RESEARCH INSTITUTES
8.5. OTHERS

9. POINT-OF-CARE GENETIC TESTING MARKET, BY GEOGRAPHY

9.1. Introduction
9.2. North America
- 9.2.1. United States
- 9.2.2. Canada
- 9.2.3. Mexico
9.3. South America
- 9.3.1. Brazil
- 9.3.2. Argentina
- 9.3.3. Others
9.4. Europe
- 9.4.1. United Kingdom
- 9.4.2. Germany
- 9.4.3. France
- 9.4.4. Italy
- 9.4.5. Spain
- 9.4.6. Others
9.5. Middle East and Africa
- 9.5.1. Saudi Arabia
- 9.5.2. UAE
- 9.5.3. Others
9.6. Asia Pacific
- 9.6.1. Japan
- 9.6.2. China
- 9.6.3. India
- 9.6.4. South Korea
- 9.6.5. Indonesia
- 9.6.6. Taiwan
- 9.6.7. Others